Overview

Update
Total Equity Funding
$53.38M in 3 Rounds from 2 Investors
Most Recent Funding
$750k Debt Financing on October 26, 2010
Headquarters:
Burlingame, CA
Description:
Juvaris BioTherapeutics develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases.
Founders:
, ,
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.juvaris.com

Company Details

Update

Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.

The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.

Funding Rounds (5) - $63.13M

Update
DateAmount / RoundValuationLead InvestorInvestors
Oct, 2010$750k / Debt Financing0
Apr, 2010$12.5M / Series B2
Jan, 2010$25M / Series B2
Aug, 2007$9M / Grant0
Jan, 2007$15.88M / Series A1

Investors (2)

Current Team (1)

Update

Offices/Locations (1)

Update
  • Office

    866 Malcolm Road

    Suite 100

    Burlingame, CA 94010

    USA

Past Team (2)

Update

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos